Leland Gershell
Stock Analyst at Oppenheimer
(4.17)
# 404
Out of 4,847 analysts
130
Total ratings
36.44%
Success rate
20.54%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Maintains: Outperform | $36 → $10 | $5.23 | +91.20% | 10 | Jun 3, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $7 | $4.38 | +59.82% | 2 | May 9, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $704 → $708 | $581.56 | +21.74% | 7 | May 9, 2025 | |
| QNCX Quince Therapeutics | Initiates: Outperform | $10 | $1.07 | +838.97% | 1 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $12 → $20 | $6.19 | +223.10% | 3 | Mar 11, 2025 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $98 | $57.02 | +71.87% | 3 | Feb 24, 2025 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Outperform | $76 | $65.95 | +15.24% | 1 | Dec 20, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $190 → $180 | $174.90 | +2.92% | 10 | Nov 15, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $48 → $52 | $17.80 | +192.13% | 2 | Nov 11, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $135 → $147 | $101.99 | +44.14% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.62 | +704.63% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.71 | - | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $73 | $78.02 | -6.43% | 8 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $15.44 | +243.26% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $38.01 | - | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $43 | $12.06 | +256.55% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $4.06 | +638.92% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $1.88 | +538.30% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $25 | $0.05 | +53,663.44% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 → $28 | $14.35 | +95.12% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $3.29 | +659.88% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $32.22 | +126.57% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $1.67 | +1,100.34% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $24.98 | +16.09% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $4.18 | +737.32% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.62 | +1,521.01% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.62 | +1,134.57% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $306.46 | - | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.70 | +666.96% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $3.99 | +2,911.29% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.10 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $360,000 | $0.67 | +54,053,954.05% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $17.42 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.93 | +2,490.67% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $11.81 | - | 5 | Mar 31, 2020 |
UroGen Pharma
Jun 3, 2025
Maintains: Outperform
Price Target: $36 → $10
Current: $5.23
Upside: +91.20%
Xeris Biopharma Holdings
May 9, 2025
Maintains: Outperform
Price Target: $6 → $7
Current: $4.38
Upside: +59.82%
argenx SE
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $581.56
Upside: +21.74%
Quince Therapeutics
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.07
Upside: +838.97%
Trevi Therapeutics
Mar 11, 2025
Maintains: Outperform
Price Target: $12 → $20
Current: $6.19
Upside: +223.10%
BioMarin Pharmaceutical
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $57.02
Upside: +71.87%
Rhythm Pharmaceuticals
Dec 20, 2024
Initiates: Outperform
Price Target: $76
Current: $65.95
Upside: +15.24%
Ascendis Pharma
Nov 15, 2024
Maintains: Outperform
Price Target: $190 → $180
Current: $174.90
Upside: +2.92%
Dianthus Therapeutics
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $17.80
Upside: +192.13%
Ligand Pharmaceuticals
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $101.99
Upside: +44.14%
Nov 5, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.62
Upside: +704.63%
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.71
Upside: -
Oct 28, 2024
Maintains: Outperform
Price Target: $65 → $73
Current: $78.02
Upside: -6.43%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $15.44
Upside: +243.26%
Oct 3, 2024
Initiates: Perform
Price Target: n/a
Current: $38.01
Upside: -
Sep 25, 2024
Maintains: Outperform
Price Target: $15 → $43
Current: $12.06
Upside: +256.55%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $4.06
Upside: +638.92%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $1.88
Upside: +538.30%
Sep 3, 2024
Maintains: Outperform
Price Target: $150 → $25
Current: $0.05
Upside: +53,663.44%
Aug 12, 2024
Reiterates: Outperform
Price Target: $31 → $28
Current: $14.35
Upside: +95.12%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $3.29
Upside: +659.88%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $32.22
Upside: +126.57%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $1.67
Upside: +1,100.34%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $24.98
Upside: +16.09%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $4.18
Upside: +737.32%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.62
Upside: +1,521.01%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.62
Upside: +1,134.57%
Oct 11, 2023
Downgrades: Perform
Price Target: n/a
Current: $306.46
Upside: -
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.70
Upside: +666.96%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $3.99
Upside: +2,911.29%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.10
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $360,000
Current: $0.67
Upside: +54,053,954.05%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $17.42
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $1.93
Upside: +2,490.67%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $11.81
Upside: -